Fievel Lim

Fievel Lim is an intellectual property attorney who focuses on patent litigation. Much of his work involves providing counsel to pharmaceutical and biotechnology companies involved in Hatch-Waxman litigation. He advises on matters in litigation at district courts, inter partes reviews (IPRs) at the Patent Trial and Appeal Board, and provides freedom-to-operate analyses. His experience includes both small molecule pharmaceuticals and biotherapeutics (biologics). Fievel has also been granted limited recognition under 37 CFR Section 11.9(b) to practice in patent matters before the United States Patent and Trademark Office.

Fievel’s litigation experience includes preparing written discovery; managing document discovery; preparing expert reports; drafting trial briefs; and motion practice. Previously, he conducted COVID-19 diagnostic research, optimized qPCR protocols for COVID-19 detection, designed qPCR primers targeting COVID-19, and tested automated COVID-19 medical devices as a research assistant at a Canadian-based biotech firm. He also drafted patent application materials for new engineering designs.